NEW ASPECTS IN THE DIAGNOSIS AND TREATMENT OF GLUCOCORTICOID OSTEOPOROSIS
https://doi.org/10.14341/osteo2013336-40
Abstract
This review summarizes the main statements of the new clinical guidelines for the diagnosis, prevention and treatment of glucocorticoid-induced osteoporosis in adult patients, published in 2013 under the auspices of the Russian Association on Osteoporosis (RAOP), the Russian Respiratory Society and the Russian Association of Rheumatologists.
References
1. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol Phys Med 2000, 39:1383—1389.
2. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000,15:933—1000.
3. Остеопороз/ под ред. О.Лесняк, Л.И.Беневоленской. — 2-е изд., перераб. и доп. — М.: ГЭОТАР-Медиа, 2009. — 272 с. — (серия «Клинические рекомендации»).
4. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». — Ярославль. ИПК «Литера». — 2013. — 48 с.
5. Lekamwasam S, Adachi JD,. Agnusdei D et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. 2012;23(9):2257—76.
6. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344—52.
7. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83—91.
8. Wallach S, Cohen S, Reid DM, Hughes RA et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67:277—85.
9. McClung MR, Geusens P, Miller PD, Zippel H et al. Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333—40.
10. Johnell O, de Laet C, Johansson H, Melton LJ et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 2002;13 (suppl 1):S14.
11. Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB, FRAX(®) Position Development Conference Members The impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture. J Clin Densitom 2011; 14:212—219.
12. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893-899
13. van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001; 51:601—607.
14. Kanis JA, Johansson H, Oden A, McCloskey E. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22:809—816.
15. Rizzoli R., Boonen S., Brandi M.-L. et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Current Medical Research & Opinion, 2013, Vol. 29, No. 4, 2013, 1—9.
16. Compston J, Reid DM, Boisdron J, et al., Group for the Respect of Ethics and Excellence in Science Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 2008; 19:1247—1250.
17. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:202—211.
18. de Nijs RN, Jacobs JW, Lems WF, et al, Investigators STOP Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.N Engl J Med 2006; 355:675—684.
19. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292—299.
20. Stoch SA, Saag KG, Greenwald M, Sebba AI, et al. Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009;36:1705—1714.
21. Yilmaz L, Ozpran K, Gündüz OH, et al. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001; 20:65—69.
22. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroidinduced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42:2309—2318.
23. Eastell R, Devogelaer J-P, Peel NFA et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000; 11:331—337.
24. Reid DM, Adami S, Devogelaer JP, Chines AA Risedronate increases bone density and reduces vertebral fracture riskwithin one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69:242—247.
25. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroidinduced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15:1006—1013.
26. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67:277—285.
27. Reid DM, Devogelaer JP, Saag K, et al, HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373:1253—1263.
28. de Nijs RN, Jacobs JW, Lems WF, et al, Investigators STOP Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355:675—684.
29. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004 Aug;15(8):589—602.
30. http://www.ema.europa.eu/docs/en_GB/document_library/Re-ferrals_document/Calcitonin_31/WC500130149.pdf
Review
For citations:
Baranova I.A., Toroptsova N.V. NEW ASPECTS IN THE DIAGNOSIS AND TREATMENT OF GLUCOCORTICOID OSTEOPOROSIS. Osteoporosis and Bone Diseases. 2013;16(3):36-40. (In Russ.) https://doi.org/10.14341/osteo2013336-40
Views:
602
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
